Garon EB, Hellmann MD, Costa EC, et al. Five-year long-term overall survival for patients with advanced NSCLC treated with pembrolizumab: Results from KEYNOTE-001. ASCO Annual Meeting 2019, abstract LBA9015.
ERBB-mutaties als biomarker voor uitkomst plaveiselcelcarcinoom van de long?
jan 2019 | Longoncologie